Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR1D | P28221 | 3/20 | 0.48 |
| ▸ | HTR1B | P28222 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893235 | 0.82 | MAPT (0.58) | MAPTTRPM8KDM4ELTA4HPLA2G2A | |
| SCHEMBL2212877 | 0.81 | ALOX5 (0.53) | MAPTLTA4HMAOBGAAMAOA | |
| SCHEMBL24159702 | 0.81 | MAOB (0.54) | MAOBMAOAL3MBTL1ALOX5 | |
| SCHEMBL2617306 | 0.79 | CYP4F2 (0.57) | MAPTTRPM8KDM4ELTA4HPLA2G2A | |
| SCHEMBL6382816 | 0.79 | ADRA1A (0.65) | MAPTTRPM8KDM4ELTA4HPLA2G2A | |
| SCHEMBL3965563 | 0.78 | CFD (0.51) | MAOBALOX5 | |
| SCHEMBL16822445 | 0.78 | ALOX5 (0.56) | MAPTMAOBGAAMAOARAB9A | |
| SCHEMBL31601164 | 0.78 | MAOB (0.58) | MAPTMAOBGAAMAOARAB9A | |
| SCHEMBL792916 | 0.78 | MAOB (0.58) | MAPTMAOBGAAMAOARAB9A | |
| Hydrochloric Acid SCHEMBL771245 | 0.76 | MAOB (0.56) | MAPTMAOBGAAMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963280-B1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2015-10-28 | — | — | EP | disclosed |
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| CN-101309909-B | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARM SPA | 2012-11-14 | — | — | CN | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| CN-101309909-A | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARM SPA (IT) | 2008-11-19 | — | — | CN | disclosed |
| EP-1963280-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1E, CACNA1I | MAPT 964/4885TRPM8 32/4885KDM4E 2032/4885 |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1I, KCNN2 | MAPT 1275/4885TRPM8 48/4885KDM4E 2642/4885 |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | CACNA1A, CACNA1I, KCNN2 | MAPT 1275/4885TRPM8 48/4885KDM4E 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.